Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Forsøket er et første-i-menneske, fase I, åpent, doseeskalerende forsøk for å vurdere sikkerheten og toleransen til ES2B-C001 kombinert med montanid eller uten montanid, hos pasienter med human epidermal vekstfaktorreseptor 2 (HER2) Uttrykker metastatisk brystkreft

15. september 2026 oppdatert av: ExpreS2ion Biotechnologies

En første-i-menneskelig fase I, åpen, dose-eskalerende studie for å vurdere sikkerhet, tolerabilitet og immunogenisitet/foreløpig antitumoraktivitet av ES2B-C001 med eller uten montanid i HER2-uttrykkende metastatisk brystkreft

The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without [adjuvant], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Graz, Østerrike
        • Medical University of Graz
      • Linz, Østerrike, 4010
        • Ordensklinikum Linz GmbH Barmherzige Schwestern
      • Vienna, Østerrike, 1090
        • Medical University Of Vienna

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients aged ≥18 years at screening visit.
  • Diagnosis of HER2-expressing locally advanced, unresectable, or metastatic BC, with HER2 IHC level 1+, 2+ (either FISH negative or positive), or IHC level 3+, after undergoing 2-3 lines of anticancer therapy.
  • Life expectancy of at least 3 months.
  • ECOG performance status 0-2.
  • Patients have adequate bone marrow, kidney, liver, heart, and lung function without clinically significant laboratory parameters as judged by the investigator.
  • 12-lead ECG without clinically significant abnormalities and no LBBB, QRS duration >140 ms, or evidence of prior infarction.
  • Recovered from side effects, adverse reactions, or adverse events due to prior therapy and/or surgery; any residual toxicities and toxicities related to current anticancer treatment must be ≤ Grade 2, except for alopecia, neuropathy or lymphoedema.
  • If female, non-pregnant, postmenopausal, or practicing reliable contraception.
  • If male, sterilized or using reliable contraception.

Exclusion Criteria:

  • Any planned intravenous chemotherapy regimens or check point inhibitors, or previous therapy with those agents during the past 1 month and the patients are neutropenic. Maintenance therapy with a stable dose of HER2-directed mAbs or treatment with antibody drug conjugates (ADCs) for metastatic BC is allowed at the discretion of the treating physician.
  • Symptomatic CNS metastatic disease requiring treatment with high dose steroids (i.e., above 10 mg of prednisone or equivalent) within 14 days prior to first administration of ES2B-C001 (with or without adjuvant).
  • Concurrent or recent (within 21 days or 5 half-lives) involvement in any other clinical trial with an investigational drug, device, or other experimental intervention.
  • Concomitant severe or uncontrolled underlying medical and/or mental disease unrelated to the tumor, which in the opinion of the investigator is likely to compromise patient safety and affect the trial's outcome.
  • Previous documented coronary artery disease or congestive heart failure (>NYHA II).
  • Echocardiography with LVEF <50%.
  • Uncontrolled hypertension.
  • Active, known, or suspected autoimmune disease, except thyroid conditions sufficiently controlled on thyroid hormone therapy, and controlled insulin dependent diabetes.
  • Necessity for long-term immunosuppression (≤ 4 mg dexamethasone may be used transiently).
  • Systemic infection requiring intravenous antibiotics within 14 days before dosing.
  • Chronic use of anti-viral agents, except for human immunodeficiency virus (HIV) or hepatitis B or C virus (HBV, HCV) treatments.
  • History of severe hypersensitivity reactions to any of the trial drug components.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Note: Administration of inactivated or recombinant vaccines/killed vaccines are allowed.
  • Birthmarks, tattoos, wounds, or skin conditions on deltoid region/buttocks that may obscure the assessment of injection site reactions.
  • Female patients who are pregnant, or lactating.
  • Any infection (including SARS-CoV-2), that in the opinion of the investigator would, upon inclusion in the trial, lead to potentially harming patients' safety or integrity.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Kohort C1: 50 ug ES2B-C001 med [adjuvans]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Eksperimentell: Kohort C2: 150 ug ES2B-C001 med [adjuvans]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Eksperimentell: Kohort C3: 450µg ES2B-C001 med eller uten [adjuvant]

Vaccine; Administration with or without [adjuvant] every third week for a total of five vaccinations.

Adjuvant; Administration together with ES2B-C001 every third week for a total of five vaccinations.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To determine the safety, tolerability, maximum tolerated dose (MTD) for ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18
  • Nature and frequency of dose-limiting toxicities (DLTs).
  • Incidence, nature and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
  • Incidence, nature and severity of injection site reactions according to FDA Guidance on Toxicity Grading Scales in Vaccine Trials (FDA, 2007).
From enrolment to the end of study at week 18

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18

Immunogenicity as humoral immune response: Total anti-HER2 Immunoglobulin G (IgG) and IgG lambda titers in sera by enzyme-linked immunosorbent assay (ELISA).

From enrolment to the end of study at week 18

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Percentage of patients with measurable disease at baseline achieving Complete Remission (CR) or Partial Response (PR) according to RECIST 1.1 as assessed by the investigator during routine follow up.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Percentage of patients with Disease Control Rate (DCR) according to RECIST 1.1 as assessed by the investigator during routine follow up.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Progression free survival (PFS) in patients with Stable Disease (SD), or PR, at the time of first dosing of ES2B-C001 alone or in combination with [adjuvant] according to RECIST 1.1.

From enrolment to the end of study at week 18
To determine the preliminary antitumor activity of ES2B-C001 alone or in combination with [adjuvant] observed.
Tidsramme: From enrolment to the end of study at week 18

Overall survival (OS)

From enrolment to the end of study at week 18
To investigate the immunogenicity of ES2B-C001 alone or in combination with [adjuvant].
Tidsramme: From enrolment to the end of study at week 18

Optionally, other immunogenicity and biomarker readouts: characterization of anti-HER2 immunoglobulins in selected sera, including isotyping (e.g. IgM, IgG and IgG subclasses IgG1-4, IgD, IgE, IgA); analysis of HER2 epitope recognition profiles; cellular immune responses; in vitro cell stimulation assays; and measuring circulating tumor DNA.

From enrolment to the end of study at week 18

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Thomas K. Jorgensen, ExpreS2ion Biotechnologies

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. juni 2025

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. september 2028

Datoer for studieregistrering

Først innsendt

12. desember 2024

Først innsendt som oppfylte QC-kriteriene

17. desember 2024

Først lagt ut (Faktiske)

24. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ES2B-C001-S01
  • 2024-516333-12-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Within the study de-identified patient data will be shared with

  • the operational study team, sponsor, auditor and for reporting of safety events to the regulatory agencies and EC
  • Data Monitoring Committees/ or other independent committees during the study
  • At the end - data listings are part of the Appendices of the CSR which will be shared to regulatory agencies and EC

IPD-deling Støtteinformasjonstype

  • SEVJE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere